The group's principal activities include biopharmaceutical development and commercialization of compounds for the treatment of cancer. Its three main business segments: acquire, develop and commercialize novel therapeutics in oncology and hematology. INNO-105 is the first drug in the company's portfolio, it has potential applications in multiple tumor types and believe brings significant advantages above the standard of care for certain cancerous conditions. In December, 2005, the group enrolled the first patients in a Phase I clinical trial of INNO-105 in adult patients with advanced solid malignancies. The objectives of the trial are to determine safety, dose, pharmacokinetic profile and its preliminary efficacy. In addition, the group also intends to leverage the development infrastructure & expect to build during the development of INNO-105 by acquiring and developing additional clinical candidates in the areas of oncology and hematology.
